课题基金 / 基金详情

AG 1343 FOR HIV+ PATIENTS--EXTENSION OF PILOT STUDY

AG 1343 FOR HIV+ PATIENTS--EXTENSION OF PILOT STUDY
AG 1343 针对 HIV 患者——试点研究的扩展
批准号：
6246946
负责人：
Martin H Markowitz
金额：
$5.86万
依托单位：
ROCKEFELLER UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-27 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246946
关键词：
AIDS therapy HIV infections antiAIDS agent antiviral agents clinical research dosage drug screening /evaluation human subject human therapy evaluation protease inhibitor

项目摘要

项目成果

Martin H Markowitz的其他基金

相似基金

相关文献

中文摘要
翻译
AG 1343是一种吸收良好的HIV-1蛋白水解酶抑制剂 在体外和体内均显示出较强的抗病毒活性。本研究 旨在继续测试AG的三种不同剂量计划 1343对于那些经历了90%的 在治疗的头28天内减少病毒载量。参与者 将每月监测药物疗效和毒性的证据。 服用AG 1343期间病毒载量增加的患者 单一疗法将不被允许与额外的FDA一起开始治疗- 批准的核苷类似物。
英文摘要
AG 1343 is a well-absorbed inhibitor of HIV-1 protease that has demonstrated potent antiviral activity in vitro and in vivo. This study is designed to continue to test three different dosage schedules of AG 1343 for both activity and safety in those patients who experienced a 90% reduction in viral load during the first 28 days of therapy. Participants will be monitored monthly for evidence of drug efficacy and toxicity. Patients who demonstrate an increase in their viral load while on AG 1343 monotherapy will not be allowed to initiate therapy with additional FDA- approved nucleoside analogues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
海外基金